Mylan working with DCGI to launch new TB drug in India
Mylan will be in a position to launch the product in India soon after receiving approvals from DCGI," Mylan's Global President and…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
DCGI
AstraZeneca India receives marketing permission for QTERN
Once-daily anti-diabetes treatment for adults with type-2 diabetes, QTERN combines two anti-hyperglycaemic agents with…
Zydus Cadila receives DCGI nod to market rabies drug in India
The novel biologic which will be marketed under the brand name, Twinrab, is indicated in combination with rabies vaccine for…
Punjab drug manufacturers call for urgent measures to curb corruption in CDSCO
In a letter outlining the issues faced by the industry, the manufacturers highlight that the reputation and future of the pharma…
Govt appoints VG Somani as new Drug Controller General
He will be be India's first full time DCGI in nearly two years after Dr G N Singh left the position in early 2018
DCGI gives limited approval to market Stempeutics’ allogeneic cell therapy
Stempeucel is used in the treatment of Buerger’s disease
DCG(I) bans 344 drugs constituting fixed dose combinations, but will it hold?
Abhijeet Das, Senior Associate, Singhania and Partners, opines that there are multiple fronts on which the aggrieved pharma…
Indian scientists develop breakthrough dengue drug
The project was jointly undertaken by DBT, ICGEB and Ranbaxy Research Laboratory and employed Ayurveda in devising the drug
In a…
Hetero receives DCG(I) approval for fixed-dose combination therapy ‘Ledipasvir-Sofosbuvir’
The product will be available under the brand name ‘Ledisof’ in India
EU’s ban of 700 pharma products will impact Indian pharma export by $1 bn
Indian govt defers FTA talks with EU